March 20, 2018Current Opinion in Cardiology
Genetic cardiomyopathies
Key result
Genetic testing improves risk stratification for patients with hypertrophic, dilated, and arrhythmogenic right ventricular cardiomyopathies and their at-risk relatives.
Population
Patients with hypertrophic, dilated, and arrhythmogenic right ventricular cardiomyopathies and their at-risk…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
NGS databases may improve variant classification for HCM/DCM/ARVC testing; leaves open prospective validation before routine adoption.
Structured PICO
P
Population
Patients with hypertrophic (HCM), dilated (DCM), and arrhythmogenic right ventricular cardiomyopathies (ARVC) and their at-risk relatives
E
Exposure
Genetic testing (using next-generation sequencing)
Genetic testing using next-generation sequencing is supported in clinical practice to improve risk stratification for patients with HCM, DCM, and ARVC and their at-risk relatives.
Cite This Study
Wilcox et al. (2018) conducted a review in Genetic cardiomyopathies (hypertrophic, dilated, and arrhythmogenic right ventricular cardiomyopathies). Genetic testing was evaluated. Genetic testing improves risk stratification for patients with hypertrophic, dilated, and arrhythmogenic right ventricular cardiomyopathies and their at-risk relatives.